# A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults After a Meal

> **NCT07333742** · PHASE1 · COMPLETED · sponsor: **LG Chem** · enrollment: 50 (actual)

## Conditions studied

- Fed Conditions
- Healthy Volunteer

## Interventions

- **DRUG:** Test drug: Fixed-dose combination (FDC) of gemigliptin/dapagliflozin/metformin 50/10/1000 mg
- **DRUG:** Reference drug: gemigliptin (Zemiglo) 50mg, Xigduo XR 10/1000 mg

## Key facts

- **NCT ID:** NCT07333742
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-09-29
- **Primary completion:** 2025-11-27
- **Final completion:** 2025-11-27
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07333742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07333742, "A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults After a Meal". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07333742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*